Pepticom joined The Alliance for Artificial Intelligence in Healthcare (AAIH)

The AAIH is a coalition of technology developers, pharmaceutical companies, and research organizations who share our goal of leveraging #AI to advance the quality of healthcare, with a special focus on AI-guided pharmaceutical development.Our advisor, Sarah Benson-Konforty, will attend our first AAIH Annual Members Meeting this May 17-18th in San Francisco.

Our CEO and co-founder, Dr. Immanuel Lerner will be speaking at TIDES Asia 2023

Dr. Immanuel Lerner, CEO and co-founder of Pepticom, will speak at the TIDES Asia conference between March 7-9. His lecture will be about The Potential and Current Application of Artificial Intelligence in Peptide Drug Discovery. The conference will take place in Kyoto, from March 7-9, and he will be available for meetings there as well […]

JP Morgan Healthcare Conference, San Francisco, January 9-10, 2023

The Pepticom Ltd. team, Our CEO Immanuel Lerner and Sarah Benson-Konforty, MD are attending the conference. You can meet them at our booth at the Health Innovation Lounge, the on-site hub of the Israeli health, tech & innovation community, and is located at 447 Sutter Street – a 2 min walk from the Westin St. Francis Hotel.

Pepticom is launching a Webinar series

The webinar series is about the world of Peptide Therapeutics, in the first couple of episodes we are hosting Dr. Tomi Sawyer, our head of the scientific advisory board. We’ll share breakthroughs in the field, what the future is and where Pepticom fits in.To watch all episodes, follow us here:

Dr. Richard Soll is joining Pepticom’s SAB

We are very excited to announce Dr. Soll joining Pepticom’s Scientific Advisory Board.Presently Senior Advisor, Strategic Initiatives at WuXi AppTec and Head of the WuXi office in Boston, Massachusetts, Dr. Soll’s contributions have led to the discovery of the HCV NS5A inhibitor in the Merck-WuXi partnership, the JAK2 inhibitor Fedratinib at TargeGen (partnered with Celgene/BMS), […]